Researchers for American pharmaceutical giant Moderna have allegedly halted early-stage clinical trials for its mRNA Epstein-Barr virus vaccine following concerns that an adolescent who participated developed a case of myocarditis, according to a report published by researcher Alex Berenson.
Around 150 adolescents and 270 people aged between 18 and 30 have been participating in the vaccine Phase 1 trial, aiming to eradicate the Epstein-Barr virus, which causes mononucleosis.
Berenson published details he says are from an internal company email states, “We [Moderna] have been informed today of an adolescent subject enrolled in Part B of the protocol that has met a pause of ‘possible case of myocarditis.’ In line with protocol guidance, this necessitates immediate suspension of all dosing for ALL adolescent subjects.”
Please think about donating below.